282 related articles for article (PubMed ID: 29883261)
1. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.
Fiorillo AA; Tully CB; Damsker JM; Nagaraju K; Hoffman EP; Heier CR
Physiol Genomics; 2018 Sep; 50(9):735-745. PubMed ID: 29883261
[TBL] [Abstract][Full Text] [Related]
2. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
[TBL] [Abstract][Full Text] [Related]
4. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
Grounds MD; Lloyd EM
J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
6. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
Heier CR; Damsker JM; Yu Q; Dillingham BC; Huynh T; Van der Meulen JH; Sali A; Miller BK; Phadke A; Scheffer L; Quinn J; Tatem K; Jordan S; Dadgar S; Rodriguez OC; Albanese C; Calhoun M; Gordish-Dressman H; Jaiswal JK; Connor EM; McCall JM; Hoffman EP; Reeves EK; Nagaraju K
EMBO Mol Med; 2013 Oct; 5(10):1569-85. PubMed ID: 24014378
[TBL] [Abstract][Full Text] [Related]
7. Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies.
Kinder TB; Heier CR; Tully CB; Van der Muelen JH; Hoffman EP; Nagaraju K; Fiorillo AA
Arthritis Rheumatol; 2020 Jul; 72(7):1170-1183. PubMed ID: 32009304
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
9. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes.
Rebane A; Runnel T; Aab A; Maslovskaja J; Rückert B; Zimmermann M; Plaas M; Kärner J; Treis A; Pihlap M; Haljasorg U; Hermann H; Nagy N; Kemeny L; Erm T; Kingo K; Li M; Boldin MP; Akdis CA
J Allergy Clin Immunol; 2014 Oct; 134(4):836-847.e11. PubMed ID: 24996260
[TBL] [Abstract][Full Text] [Related]
11. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.
Liu X; Wang Y; Gutierrez JS; Damsker JM; Nagaraju K; Hoffman EP; Ortlund EA
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24285-24293. PubMed ID: 32917814
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.
Hoffman EP; Riddle V; Siegler MA; Dickerson D; Backonja M; Kramer WG; Nagaraju K; Gordish-Dressman H; Damsker JM; McCall JM
Steroids; 2018 Jun; 134():43-52. PubMed ID: 29524454
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
[TBL] [Abstract][Full Text] [Related]
14. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients.
Jeanson-Leh L; Lameth J; Krimi S; Buisset J; Amor F; Le Guiner C; Barthélémy I; Servais L; Blot S; Voit T; Israeli D
Am J Pathol; 2014 Nov; 184(11):2885-98. PubMed ID: 25194663
[TBL] [Abstract][Full Text] [Related]
15. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11.
Ashraf U; Zhu B; Ye J; Wan S; Nie Y; Chen Z; Cui M; Wang C; Duan X; Zhang H; Chen H; Cao S
J Virol; 2016 May; 90(9):4780-4795. PubMed ID: 26937036
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
18. MiR-199-3p enhances muscle regeneration and ameliorates aged muscle and muscular dystrophy.
Fukuoka M; Fujita H; Numao K; Nakamura Y; Shimizu H; Sekiguchi M; Hohjoh H
Commun Biol; 2021 Mar; 4(1):427. PubMed ID: 33782502
[TBL] [Abstract][Full Text] [Related]
19. Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs.
Fiorillo AA; Heier CR; Huang YF; Tully CB; Punga T; Punga AR
Front Immunol; 2020; 11():151. PubMed ID: 32153563
[TBL] [Abstract][Full Text] [Related]
20. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
Greco S; De Simone M; Colussi C; Zaccagnini G; Fasanaro P; Pescatori M; Cardani R; Perbellini R; Isaia E; Sale P; Meola G; Capogrossi MC; Gaetano C; Martelli F
FASEB J; 2009 Oct; 23(10):3335-46. PubMed ID: 19528256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
